The latest price target for Adaptimmune Therapeutics (NASDAQ:ADAP) was reported by Barclays on May 14, 2025. The analyst firm set a price target for $0.46 expecting ADAP to rise to within 12 months (a possible 59.22% upside). 14 analyst firms have reported ratings in the last year.

The latest analyst rating for Adaptimmune Therapeutics (NASDAQ:ADAP) was provided by Barclays, and Adaptimmune Therapeutics maintained their underweight rating.

The last upgrade for Adaptimmune Therapeutics PLC happened on January 3, 2023 when Guggenheim raised their price target to $5. Guggenheim previously had a neutral for Adaptimmune Therapeutics PLC.

There is no last downgrade for Adaptimmune Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptimmune Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptimmune Therapeutics was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.

While ratings are subjective and will change, the latest Adaptimmune Therapeutics (ADAP) rating was a maintained with a price target of $1.00 to $0.46. The current price Adaptimmune Therapeutics (ADAP) is trading at is $0.29, which is out of the analyst’s predicted range.